The
slide to be stained for CDX2
comprised:
1. Appendix, 2. Pancreas, blood type A, 3. Colon adenocarcinoma, 4.
Ovarian mucinous cystadenoma, 5. Colon adenocarcinoma.
All tissues were fixed in 10% neutral buffered formalin.
Criteria for assessing a CDX2 staining as optimal included:
- A strong, distinct nuclear staining of
virtually all the epithelial cells in the appendix
- A moderate to strong, distinct nuclear
staining of virtually all the neoplastic cells in the two colon
adenocarcinomas
- An at least weak to moderate, distinct
nuclear staining in scattered cells in the ovarian mucinous
cystadenoma.
- An at least weak to moderate and distinct
nuclear reaction in the majority of the duct epithelial cells in
the pancreas.
A weak cytoplasmic reaction in cells with
strong nuclear staining was accepted.
All other cells should be negative.
93 laboratories participated in this
assessment. 46 % achieved a sufficient mark. In table 1 the
antibodies (Abs) used and marks are summarized.
Table 1.
Abs and
assessment marks
for CDX2, run 27
|
Concentrated Abs |
N |
Vendor |
Optimal |
Good |
Borderl. |
Poor |
Suff.1 |
Suff. OPS2 |
|
mAb
clone CDX2-88 |
35
3 |
BioGenex
Biocare |
7 |
6 |
9 |
16 |
36 % |
50 % |
|
mAb clone AMT28 |
21 |
Novocastra |
3 |
4 |
5 |
9 |
33 % |
60 % |
|
mAb clone
DAK-CDX2 |
4 |
Dako |
2 |
2 |
0 |
0 |
- |
- |
|
mAb clone SFI-2 |
1 |
Master Diagnostica |
0 |
0 |
0 |
1 |
- |
- |
|
Ready-To-Use Abs |
|
|
|
|
|
|
|
|
|
mAb
clone DAK-CDX2
IS080/IR080 |
15 |
Dako |
13 |
2 |
0 |
0 |
100 % |
100 % |
|
mAb clone
CDX2-88, AM392 |
6 |
BioGenex |
0 |
0 |
0 |
6 |
- |
- |
|
mAb clone
CDX2-88, IP226 |
1 |
Biocare |
0 |
0 |
0 |
1 |
- |
- |
|
mAb clone
CDX2-88, E087 |
2 |
Linaris |
0 |
1 |
1 |
0 |
- |
- |
|
rmAb clone
EPR2764Y, 760-4380 |
4
1 |
Ventana
Cell Marque |
1 |
2 |
1 |
1 |
60 % |
100 % |
|
Total |
93 |
|
26 |
17 |
16 |
34 |
- |
- |
|
Proportion |
|
|
28 % |
18 % |
17 % |
37 % |
46 % |
- |
1) Proportion of sufficient stains
(optimal or good), 2) Proportion of sufficient stains with optimal
protocol settings only, see below.
Following central protocol parameters were used to obtain an optimal
staining:
Concentrated Abs
mAb clone CDX2-88: The protocols giving an optimal result
were all based on heat induced epitope retrieval (HIER) in either
Tris-EDTA/EGTA pH 9 (2/11)*, Target Retrieval Solution pH 9
(EnVision FLEX TRS high pH, Dako, (2/6), Bond Epitope Retrieval
Solution 2 (Bond, Leica) (2/4) or Citrate pH 6 (1/4) as the
retrieval buffer. The mAb was typically diluted in the range of
1:20– 1:100 depending on the total sensitivity of the protocol
employed. Using these protocol settings 9 out of 18 (50 %)
laboratories produced a sufficient staining (optimal or good).
*(number of optimal results/number of
laboratories using this buffer)
mAb clone AMT28: The protocols giving an optimal result were
all based on heat induced epitope retrieval (HIER) using either
Tris-EDTA/EGTA pH 9 (2/10) or Citrate pH 6 (1/2) as the retrieval
buffer. The mAb was typically diluted in the range of 1:50– 1:100
depending on the total sensitivity of the protocol employed. Using
these protocol settings 6 out of 10 (60%) laboratories produced a
sufficient staining.
mAb clone DAK-CDX2: The protocols giving an optimal result
were both based on heat induced epitope retrieval (HIER) using
either Tris-EDTA/EGTA pH 9 (1/1) or Cell Conditioning 1 (BenchMark,
Ventana) (1/2) as the retrieval buffer. The mAb was typically
diluted in the range of 1:20– 1:25 depending on the total
sensitivity of the protocol employed. Using these protocol settings
3 out of 3 (100 %) laboratories produced a sufficient staining.
Ready-To-Use Abs
mAb clone DAK-CDX2 (prod. no IS080/IR080, Dako): The
protocols giving an optimal result were all based on HIER in PT-Link
using Target Retrieval Solution pH 9 (EnVision FLEX TRS high pH),
an incubation time of 20 or 30 min in the primary Ab and EnVision
Flex (K8000) or Flex+ (K8002) as the detection system. 1 lab used
standard Cell Conditioning 1 (BenchMark, Ventana), an incubation
time of 32 min in the primary Ab and Ultra View (760-500) as the
detection system. Using these protocol settings 15 out of 15 (100 %)
laboratories produced a sufficient staining.
rmAb clone EPR2764Y (prod. no. 760-4380, Ventana/Cell
Marque), the protocol giving an optimal result was based on HIER
using standard Cell Conditioning 1 standard (BenchMark, Ventana), an
incubation time of 32 min in the primary Ab and Ultra View (760-500)
as the detection system. Using these protocol settings 2 out of 2
(100 %) laboratories produced a sufficient staining.
The most frequent causes of insufficient stains were:
- Too low concentration of the primary antibody
- Insufficient HIER
- Use of low sensitive detection systems
- Less successful ready-to-use (RTU) mAb clone CDX2-88
In this assessment the prevalent feature of an insufficient staining
was a too weak or completely false negative
staining reaction of the cells expected to be demonstrated. Virtually
all laboratories were able to demonstrate CDX2 in high antigen
expressing cells in the appendix and
one of the colon adenocarcinomas (specimen no.
3) in the multi-tissue block, whereas the low expressing cells in
other colon adenocarcinoma (specimen no. 5), the ovarian mucinous
cystadenoma and the epithelial cells of the intercalating ducts in
the pancreas could only be demonstrated with an optimal protocol.
In this assessment the two newly launched Abs for CDX2, mAb clone
DAK-CDX2 and rmAb EPR2764Y gave a higher pass rate than the old mAb
clones CDX2-88 and AMT28. E.g., all 19 protocols based on the mAb
clone DAK-CDX2 gave a sufficient result, whereas only 7 out of 21
protocols based on the clone AMT28 gave a sufficient result. The 2
new Abs were primarily applied as RTU formats within a predefined RTU system.
The superior performance reflects credit on the producers!
As observed in the previous assessment of CDX2 (run 22, 2008), the mAb clone
CDX2-88 from BioGenex frequently gave a false positive cytoplasmic
staining in the epithelial cells of the pancreas, blood type A due
to the "Mouse Ascites Golgi" (MAG) reaction.
In concordance with previous observations, pancreas is
a recommendable positive control for CDX2 provided that a distinct nuclear reaction is seen in the majority of
the duct epithelial cells. Virtually all labs obtaining this
reaction pattern in the pancreas were assessed as sufficient.
This was the second assessment of CDX2 in NordiQC. The
proportion of sufficient results declined from 64 % in run 22, 2008
to 46 % in the current run – see table 2. The lower pass rate is
probably due to more challenging tissue material circulated and many
laboratories participating for the first time.
Table 2:
Proportion of sufficient results for CDX2 in the two NordiQC runs
performed
| |
Run 22
2008 |
Run 27 2009 |
|
Participants, n= |
56 |
93 |
|
Sufficient results |
64 % |
46 % |
Conclusion
The mAbs clones CDX2-88, AMT28, DAK-CDX2 and the rmAb clone
EPR2764Y can all be used to obtain an optimal demonstration of CDX2.
The new mAb clone DAK-CDX2 and the rmAb clone EPR2764Y gave in this
assessment a superior performance. For all four Abs efficient HIER
and a sensitive detection system is mandatory to obtain an optimal
staining. Pancreas is an appropriate control: A weak to moderate, distinct nuclear reaction in the majority of the duct epithelial
cells in the pancreas must be seen.
|